![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult atypical hemolytic uremic syndrome (aHUS) patients who are naive to complement inhibitor therapy
![](https://studyfinder.umn.edu/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcU1FIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--61057557dff3e770b20dd9e1c898aace70cdd98f/Image%2004.jpg)
Recruiting
To evaluate the efficacy and safety of iptacopan at a dose of 200 mg twice a day for 52 weeks in patients with atypical hemolytic uremic syndrome (aHUS).
Male or Female
18 years and over
Inclusion Criteria:
• at least 18 years old
• evidence of active Thrombotic Microangiopathy (TMA)
Exclusion Criteria:
• previous or ongoing treatment with complement inhibitors, including anti-C5 antibody
• ADAMTS13 deficiency
• positive test for Shiga toxin * direct Coombs test
• had a bone marrow transplant or hematopoietic stem cell transplant, or a heart, lung, small bowel, pancreas or live transplant
Drug: Iptacopan
Blood Disorders, Kidney, Prostate & Urinary, Rare Diseases
Clinics and Surgery Center (CSC)
Karen Omlung - seve0024@umn.edu
Nattawat Klomjit
PHASE3
STUDY00020503
See this study on ClinicalTrials.gov